Mammographic screening detects low-risk tumor biology breast cancers

Breast Cancer Research and Treatment

Volumn 144, Issue 1, 2014, Pages 103-111

  Drukker, C A ^a   Schmidt, M K ^a   Rutgers, E J T ^a   Cardoso, F ^b   Kerlikowske, K ^c   Esserman, L J ^d   Van Leeuwen, F E ^a   Pijnappel, R M ^e   Slaets, L ^f   Bogaerts, J ^f   Van'T Veer, L J ^g,h  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Champalimaud Cancer Centre   (Portugal)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f EORTC DATA CENTER   (Belgium)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Agendia NV   (Netherlands)

Author keywords

70 Gene signature; Breast cancer; Film screen mammography; Full field digital mammography; Screening

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIGITAL MAMMOGRAPHY; DUTCH; ETHNIC GROUP; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL;

AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; RISK; TRANSCRIPTOME;

EID: 84894674291     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2830-5     Document Type: Article

References (23)

1. Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, Wallis M, Lawrence G (2011) Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 117:1360-1368
2. Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retel VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ (2011) Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 130:725-734
3. Esserman LJ, Thompson IM, Reid B (2013) Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 310(8):797-798
4. Lundgren B, Helleberg A (1982) Single oblique-view mammography for periodic screening for breast cancer in women. J Natl Cancer Inst 68:351-355
5. Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E (2012) Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 19(Suppl 1):42-56
6. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, De Koning HJ (2011) Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 33:111-121
7. Mook S, van't Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, Visser O, Schmidt MK (2011) Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103:585-597
8. Azim HA Jr, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, Andre F, Loi S, Swanton C (2013) Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 24:647-654
9. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
10. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
11. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192
12. Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, van't Veer LJ, van de Vijver MJ (2009) Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 117:483-495
13. Drukker CA, Bueno-de-Mesquita JM, Retel VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC (2013) A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 133:929-936
14. National Evaluation Team for Breast Cancer Screening in the Netherlands: NETB report 2012
15. Bluekens AM, Holland R, Karssemeijer N, Broeders MJ, den Heeten GJ (2012) Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: a multicenter study. Radiology 265:707-714
16. Vinnicombe S, Pinto Pereira SM, McCormack VA, Shiel S, Perry N, Dos Santos Silva IM (2009) Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data. Radiology 251:347-358
17. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D'Orsi C, Jong R, Rebner M (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1773-1783
18. Kerlikowske K, Hubbard RA, Miglioretti DL, Geller BM, Yankaskas BC, Lehman CD, Taplin SH, Sickles EA (2011) Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med 155:493-502
19. Cardoso F, van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729-735
20. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, van't Veer LJ, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F (2011) The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 47:2742-2749
21. De Koning HJ, Fracheboud J, Boer R, Verbeek AL, Collette HJ, Hendriks JH, van Ineveld BM, de Bruyn AE, van der Maas PJ (1995) Nation-wide breast cancer screening in The Netherlands: support for breast-cancer mortality reduction. National Evaluation Team for Breast Cancer Screening (NETB). Int J Cancer 60:777-780
22. Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302:1685-1692
23. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M (2013) The benefits and harms of breast cancer screening: an independent review. Br J Cancer 108:2205-2240